These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 34777381)
1. Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward. Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F Front Immunol; 2021; 12():765097. PubMed ID: 34777381 [TBL] [Abstract][Full Text] [Related]
2. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease. Pehlivan KC; Duncan BB; Lee DW Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708 [TBL] [Abstract][Full Text] [Related]
3. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Vairy S; Garcia JL; Teira P; Bittencourt H Drug Des Devel Ther; 2018; 12():3885-3898. PubMed ID: 30518999 [TBL] [Abstract][Full Text] [Related]
4. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764 [TBL] [Abstract][Full Text] [Related]
5. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295 [TBL] [Abstract][Full Text] [Related]
6. CD4 Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717 [TBL] [Abstract][Full Text] [Related]
7. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Cerrano M; Ruella M; Perales MA; Vitale C; Faraci DG; Giaccone L; Coscia M; Maloy M; Sanchez-Escamilla M; Elsabah H; Fadul A; Maffini E; Pittari G; Bruno B Front Immunol; 2020; 11():888. PubMed ID: 32477359 [TBL] [Abstract][Full Text] [Related]
8. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. Ahmad A; Uddin S; Steinhoff M Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160 [TBL] [Abstract][Full Text] [Related]
9. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes. Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021. Gauthier J; Turtle CJ Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068 [TBL] [Abstract][Full Text] [Related]
12. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F Stem Cell Res Ther; 2021 Oct; 12(1):527. PubMed ID: 34620233 [TBL] [Abstract][Full Text] [Related]
13. Clinical use of CAR T-cells in treating acute lymphoblastic leukemia. Korkmaz S Transfus Apher Sci; 2023 Apr; 62(2):103666. PubMed ID: 36868895 [TBL] [Abstract][Full Text] [Related]
14. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review. Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234 [TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096 [TBL] [Abstract][Full Text] [Related]
16. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292 [TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]
18. CAR T-Cell Therapy in the Older Person: Indications and Risks. Shouse G; Danilov AV; Artz A Curr Oncol Rep; 2022 Sep; 24(9):1189-1199. PubMed ID: 35420395 [TBL] [Abstract][Full Text] [Related]
19. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386 [TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL). Shouse G; Budde E; Forman S Cancer Treat Res; 2021; 181():179-196. PubMed ID: 34626362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]